Skip to content
DE

PalopegteriparatidePTH replacement prodrug

Palopegteriparatide gradually releases an active fragment of parathyroid hormone. It is designed for chronic hypoparathyroidism, where controlling calcium with supplements alone does not replace all of the missing hormone’s functions.

What is Palopegteriparatide?

Palopegteriparatide is a parathyroid-hormone prodrug. EU Yorvipath is used in adults with chronic hypoparathyroidism. 3

How it works

The preparation gradually releases PTH(1–34), replacing part of the missing hormone signal involved in calcium regulation.

Effects studied

Calcium control with less conventional replacement

The PaTHway study assessed maintaining blood calcium while reducing calcium supplements and active vitamin D. 1

Evidence: A treatment-control outcome in hypoparathyroidism, rather than a demonstration that the underlying condition is cured.

What does the evidence show?

Hypoparathyroidism trial and checked EU indication

More than a calcium deficiency

Parathyroid hormone helps coordinate calcium and phosphate across the kidneys, bone and vitamin D system. In hypoparathyroidism, the missing signal affects that coordination. Giving calcium and active vitamin D can help manage blood calcium, but it does not recreate the whole hormonal pattern.

A prolonged replacement signal

Palopegteriparatide is a prodrug: its carrier gradually releases PTH(1–34), the active hormone fragment. The release pattern is central to its intended effect. Medicines containing a PTH fragment are therefore not necessarily equivalent; formulation and treatment purpose matter.

What a meaningful result looks like

The retained PaTHway trial assessed whether people could maintain blood calcium while reducing reliance on conventional calcium and active vitamin D treatment. That is an important practical outcome, but longer-term kidney and skeletal outcomes deserve separate attention. A normal blood test is one part of a successful replacement strategy. 1

Why monitoring remains necessary

The EU authorisation for Yorvipath concerns adults with chronic hypoparathyroidism. Replacement must be balanced with other treatments that affect calcium, because both high and low levels can cause problems. Changes to conventional treatment need to be made within a supervised care plan. A trial headline cannot provide those instructions. 2 3

Safety & status

Both high and low blood calcium can occur, particularly around treatment changes. Product-specific monitoring and adjustment are central to safe use. 2 3

Country and product status

EU Yorvipath indication checked for adults with chronic hypoparathyroidism. Swiss status not checked.

Frequently asked questions

Is it simply another calcium supplement?

No. It provides a hormone signal involved in calcium regulation rather than supplying calcium itself.

Does reducing supplements mean the condition has resolved?

No. Reduced reliance on calcium and active vitamin D can reflect successful hormone replacement, not a cure. 1

Further reading

Concept illustration for Palopegteriparatide.GuidePalopegteriparatide (Yorvipath): uses, how it works and side effectsPalopegteriparatide replaces missing parathyroid hormone in adults with hypoparathyroidism. How the medicine works, what it is used for and which risks are described.Read the article

Sources

This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.

  1. Retained paper reference Archive research lead · Retained archive reference; not independently checked for this draft
  2. Retained source reference Archive research lead · Retained archive reference; not independently checked for this draft
  3. EMA · Yorvipath Primary source checked · EU adult chronic hypoparathyroidism indication and authorisation date checked in EMA search result on 27 October 2026; not a full independent trial review.
Research provenance

This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.